CA
NZ
UK
AU
IND
US
Mustang Bio, Inc. (NASDAQ: MBIO), a cell-and-gene-therapy developer, sits in a precarious spot on Nasdaq: its shares trade well below $1 and the company is racing a listing-compliance clock. The stock eased modestly in recent trading, but the more consequential backdrop is a Nasdaq …
● Few small-cap biotech names capture the tension between clinical promise and financial fragility as vividly as Moleculin Biotech.
A quote of a hundred-thousandth of a cent tends to tell its own story. Medican Enterprises Inc (OTC:MDCN) trades on the over-the-counter market at effectively nothing, and the flat tape reflects a company that stopped reporting to regulators years ago rather than one poised …
Medicus Pharma Ltd (NASDAQ: MDCX) enters the autumn as a company mid-reinvention. The clinical-stage drug developer, which trades below 20 cents and carries a market value of only about $11 million, has begun repositioning itself as a precision oncology-led biotechnology business. With a fresh …
● In fact, the recent news flow has been positive: alongside the strong quarter, Lake Street raised its price target on LENSAR to $13 from $10 on 20 August while maintaining a bullish stance.
● The modest positive session in the original framing is a price move, not a discrete catalyst; the meaningful driver is the pendingAcquisitionitself.
Lantern Pharma has spent 2026 leaning hard into a pitch that blends oncologyDrug Developmentwith artificial intelligence, and the small-cap has generated a steady stream of announcements. Yet the stock has drifted lower, trading near $1.77 in early September with a marketCapitalizationaround $23 million. For …
A roughly 5.5% single-session drop in Lineage Cell Therapeutics, Inc (NYSE American:LCTX) fits a pattern familiar to small-cap biotech investors: sharp moves with no obvious explanation. Underneath that daily swing sits a more durable story, a clinical-stage developer of allogeneic cell therapies anchored by …
LENZ Therapeutics, Inc (NASDAQ:LENZ) has spent 2026 transitioning from a clinical-stage hopeful into a commercial eye-care company, and its shares have been volatile as investors gauge the early trajectory of its first approved product.
After a difficult fiscal year, LifeVantage Corporation (NASDAQ: LFVN) is drawing renewed interest from small-cap investors trying to gauge whether a turnaround is taking shape. The nutrition and personal-care company's shares recently ticked higher to around $6.51, giving it a marketCapitalizationnear $82 million, and …
Please wait processing your request...